Phase I Trial Tests New PCSK9 Inhibitor JS002 for Cholesterol Control
A randomized, double-blind, placebo-controlled dose-escalation study evaluates the safety and pharmacodynamics of JS002, a humanized anti-PCSK9 antibody.
Summary
JS002 is a recombinant humanized monoclonal antibody targeting PCSK9, a protein that limits the liver's ability to clear LDL cholesterol from the blood. This Phase Ia trial from Shanghai Junshi Bioscience tested single doses of JS002 in healthy volunteers across eight dose cohorts — five subcutaneous and three intravenous — ranging from 15 mg to 450 mg. The randomized, double-blind, placebo-controlled design aimed to establish the safety profile, tolerability, pharmacokinetics, and pharmacodynamic effects of the drug. Each cohort enrolled 8 to 12 subjects with a 3:1 active-to-placebo ratio, and each participant was followed for 84 days. This early-phase data is foundational for advancing JS002 toward trials in patients with hypercholesterolemia.
Detailed Summary
High LDL cholesterol remains a leading modifiable risk factor for cardiovascular disease and premature death. While PCSK9 inhibitors like evolocumab and alirocumab have transformed cholesterol management, access and cost remain barriers globally. JS002 represents a biosimilar or next-generation anti-PCSK9 monoclonal antibody developed in China with potential to broaden this class of therapy.
This Phase Ia trial enrolled healthy subjects to evaluate single ascending doses of JS002 via subcutaneous injection across five dose levels — 15 mg, 50 mg, 150 mg, 300 mg, and 450 mg — and via intravenous infusion at three dose levels — 15 mg, 150 mg, and 450 mg. The randomized, double-blind, placebo-controlled design allocated participants in a 3:1 ratio of active drug to placebo within each cohort of 8 to 12 subjects. Each participant was monitored for 84 days, enabling assessment of drug behavior over an extended post-dose window.
The primary outcomes focused on safety, tolerability, pharmacokinetics, and pharmacodynamics. Pharmacodynamic endpoints for a PCSK9 inhibitor in healthy subjects would typically include reductions in LDL cholesterol and free PCSK9 protein levels. The dual-route design also allows comparison of subcutaneous versus intravenous delivery in terms of bioavailability and concentration-time profiles.
If JS002 demonstrates a favorable safety profile and meaningful LDL-lowering pharmacodynamics consistent with the PCSK9 inhibitor class, it would support advancement to Phase II and III trials in patients with hypercholesterolemia, including those with familial hypercholesterolemia or statin intolerance.
Key caveats include the early-phase nature of this study in healthy subjects, the small cohort sizes, and the absence of published efficacy results in the public domain. This summary is based on the registered clinical trial record and abstract only; full results have not been reviewed.
Key Findings
- JS002 tested across 8 dose cohorts (15–450 mg) via subcutaneous and intravenous routes in healthy subjects.
- Randomized, double-blind, placebo-controlled design with 3:1 drug-to-placebo allocation per cohort.
- 84-day follow-up period allows assessment of sustained pharmacodynamic LDL-lowering effects.
- Phase Ia design prioritizes establishing safety, tolerability, and pharmacokinetic profile before patient trials.
- Dual-route administration enables direct comparison of subcutaneous versus IV bioavailability.
Methodology
This was a Phase Ia, randomized, double-blind, placebo-controlled single ascending dose study in healthy subjects. Eight cohorts covered five subcutaneous dose levels (15, 50, 150, 300, 450 mg) and three intravenous dose levels (15, 150, 450 mg), each enrolling 8–12 subjects in a 3:1 active-to-placebo ratio. The observation window was 84 days per subject.
Study Limitations
This summary is based on the trial registration abstract only, as the full study data are not publicly available. The study was conducted in healthy volunteers, limiting direct inference about efficacy or safety in patients with hypercholesterolemia. Cohort sizes of 8–12 subjects provide limited statistical power to detect rare adverse events.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: